A U.S. federal judge rejected Swiss drugmaker Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from ...

The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in ...

Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

Sales of Kisqali, which treats metastatic breast cancer, surged 64% globally on a constant currency basis in the three months to June, the company said in its second-quarter sales report. That ...

The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...

NVS beats on Q2 earnings, raises 2025 income outlook on strong drug sales, but Cosentyx miss and CFO exit weigh on shares.

Novartis could soon face generic competition for Entresto after judge's ruling.

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug ...

In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO ...

A federal judge has denied Novartis (SIX:NOVN)’ request for a preliminary injunction that would have prevented MSN Pharmaceuticals from selling a generic version of heart medication Entresto.

A Delaware federal judge has ruled that Novartis cannot prevent MSN Pharmaceuticals from introducing a generic version of its ...